PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
PTIXBOSTON--(BUSINESS WIRE)--PureTech Demonstrates Strategic and Scientific Leadership in Idiopathic Pulmonary Fibrosis at 2025 IPF Summit
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
PTIXBOSTON--(BUSINESS WIRE)--PureTech Announces the Launch of Celea Therapeutics with a Mission to Transform the Treatment of Respiratory Diseases
Protagenic Therapeutics (PTIX) Stock Soars 240% On Phytanix Merger
PTIXProtagenic Therapeutics shares soared 240% Monday on its all-stock merger with Phytanix Bio. New Phytanix targets CNS disorders with an expanded diverse pipeline and experienced team.
Protagenic Therapeutics Shares Resume Trade
PTIXAs Calculated On A Fully Diluted Basis, Post-Combination Pre-Financing Ownership Will Be Approximately 35% For The Pre-Combination Stockholders Of The Company And Approximately 65% For Phytanix Bio Stockholders.
PTIXProtagenic Therapeutics And Phytanix Enter Business Combination In All-Stock Transaction
PTIXProtagenic Therapeutics Q1 EPS $(2.75) Up From $(5.44) YoY
PTIXTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
PTIXProtagenic Therapeutics shares are trading higher after the company announced it filed for an offering of 5.84 million shares of common stock.
PTIXProtagenic Therapeutics Inc Files For Offering Of Up To 5.84M Shares Of Common Stock By Selling Stockholders
PTIXProtagenic Therapeutics shares are trading lower. The company reported safety data from the single dose portion of its Phase 1 trial involving PT00114.
PTIXProtagenic Therapeutics' Reports Safety Data From Single Dose Portion Of Phase 1 Trial Involving PT00114
PTIX